<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549040</url>
  </required_header>
  <id_info>
    <org_study_id>1439-046</org_study_id>
    <secondary_id>2015-002702-36</secondary_id>
    <nct_id>NCT02549040</nct_id>
  </id_info>
  <brief_title>Bioavailability of MK-1439 Experimental Nano Formulations in Healthy Adults (MK-1439-046)</brief_title>
  <official_title>A Rapid Pharmacokinetic Trial of the Bioavailability of Four MK-1439 Nano Formulations in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate and compare the relative bioavailability of different MK-1439
      experimental nano formulations (NFs) with that of a MK-1439 film coated tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf) of MK-1439 following a single administration of MK-1439</measure>
    <time_frame>Periods 1 to 5 at the following Day 1 time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to last time (AUC 0-last) with quantifiable MK-1439 following a single administration of MK-1439</measure>
    <time_frame>Periods 1 to 5 at the following Day 1 time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of MK-1439 following a single administration of MK-1439</measure>
    <time_frame>Periods 1 to 5 at the following Day 1 time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of MK-1439 at 24 hours post-dose (C24hr) following a single administration of MK-1439</measure>
    <time_frame>Periods 1 to 5: 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experienced at least one adverse event</measure>
    <time_frame>Up to 16 days after last dose of study treatment (up to approximately 92 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who discontinued study due to an adverse event</measure>
    <time_frame>Up to 4 days after last dose of study treatment (up to approximately 76 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to 48 hours (AUC 0-48 hr.) post-dose of MK-1439 following a single administration of MK-1439</measure>
    <time_frame>Periods 1 to 5 at the following Day 1 time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Human Immunodeficiency Virus-1 (HIV-1)</condition>
  <arm_group>
    <arm_group_label>MK-1439 fixed sequence treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a minimum 10 hour overnight fast, participants are treated with a single oral dose of MK-1439 over a 5 Period fixed sequence. Each period is separated by a 14 day washout.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1439 film coated tablet</intervention_name>
    <description>A single MK-1439 film coated tablet, administered orally at the start of Period 2</description>
    <arm_group_label>MK-1439 fixed sequence treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1439 NF</intervention_name>
    <description>A single MK-1439 NF, administered orally at the start of Periods 1, 3, 4, and 5.</description>
    <arm_group_label>MK-1439 fixed sequence treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

